Full text is available at the source.
Abstract
SM102-based lipid nanoparticles (LNPs) showed significantly higher transfection efficiency than MC3-based LNPs for ocular mRNA delivery.
- Clinically approved ionizable lipids DLin-MC3-DMA and SM102 were evaluated for their effectiveness in delivering mRNA to the eye.
- The study assessed the physicochemical properties, delivery efficiency, and distribution patterns of these LNPs in the ocular environment.
- SM102-LNPs demonstrated superior performance in transfecting retinal cells compared to MC3-LNPs.
- Intravitreal administration of SM102-LNPs led to more efficient expression of mRNA in the eye with limited systemic distribution.
- Long-term safety assessments of SM102-LNPs indicated excellent biocompatibility over a five-month observation period.
Simplified